Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer

Aim: To determine the role of two antiapoptotic proteins of the inhibitor of apoptosis protein family, cellular inhibitor of apoptosis protein 1 (cIAP1) and cellular inhibitor of apoptosis protein 2 (cIAP2), in human pancreatic carcinogenesis. Methods: mRNA levels were measured in pancreatic tissues and pancreatic cancer cell lines by quantitative reverse transcriptase PCR. Protein expression was assessed in pancreatic cancer cell lines by immunoblotting and in pancreatic tissues by immunohistochemistry, and correlated with pathological and survival data. Results: cIAP1 expression was constantly high in non-neoplastic pancreatic tissues, in pancreatic intraepithelial neoplasia (PanIN) lesions, as well as in a subset of primary and metastatic pancreatic ductal adenocarcinomas (PDAC), and a preferential cytoplasmatic localisation was observed in the tumour tissues. cIAP1 expression was rare in a cohort of cystic tumours. cIAP2 mRNA levels were significantly higher (2.4 fold) in PDAC than in normal tissues. cIAP2 protein was overexpressed in PDAC, and was detectable in low- and high-grade PanIN lesions. Moreover, cIAP2 was often expressed in pancreatic cystic tumours. cIAP1 and cIAP2 mRNA and protein were detected in all the examined cell lines. Survival analysis revealed a shorter survival in patients with cIAP1/cIAP2-positive tumours. Conclusions: cIAP1 might contribute to the regulation of the apoptotic process in the normal and in the neoplastic pancreas, depending on its subcellular localisation. Overexpression of cIAP2 is a common and early event in the progression of pancreatic cancer, and could therefore potentially influence the important pathophysiological aspects of PDAC, such as anoikis or chemoresistance.

[1]  K. Xia,et al.  XIAP Is Related to the Chemoresistance and Inhibited Its Expression by RNA Interference Sensitize Pancreatic Carcinoma Cells to Chemotherapeutics , 2006, Pancreas.

[2]  H. Friess,et al.  Tenascin C and annexin II expression in the process of pancreatic carcinogenesis , 2006, The Journal of pathology.

[3]  G. Salvesen,et al.  The Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases* , 2006, Journal of Biological Chemistry.

[4]  G. Giaccone,et al.  Expression and localization of inhibitor of apoptosis proteins in normal human tissues. , 2006, Human pathology.

[5]  R. Kerbel,et al.  ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells , 2005, Journal of Biological Chemistry.

[6]  N. Tsuji,et al.  Introduction of a survivin gene-specific small inhibitory RNA inhibits growth of pancreatic cancer cells. , 2005, Anticancer research.

[7]  C. Duckett,et al.  Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. , 2005, The Journal of clinical investigation.

[8]  S. Miyatake,et al.  Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. , 2005, Surgery.

[9]  B. Vincenzi,et al.  Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients , 2005, British Journal of Cancer.

[10]  V. Diehl,et al.  Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759] , 2005, BMC Cancer.

[11]  John Calvin Reed,et al.  cIAP1 Localizes to the nuclear compartment and modulates the cell cycle. , 2005, Cancer research.

[12]  M. Löhr,et al.  Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. , 2005, Neoplasia.

[13]  M. Ogawa,et al.  Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer. , 2004, International journal of oncology.

[14]  G. Giaccone,et al.  Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. , 2004, Experimental cell research.

[15]  Hidetaka Mochizuki,et al.  The Correlation Between Cytoplasmic Overexpression of Epidermal Growth Factor Receptor and Tumor Aggressiveness: Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2004, Pancreas.

[16]  H. Friess,et al.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma , 2004, The British journal of surgery.

[17]  H. Patel,et al.  Tissue microarrays: a current medical research tool , 2004, Current medical research and opinion.

[18]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[19]  H. Kalthoff,et al.  Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells , 2003, British Journal of Cancer.

[20]  Lily Yang,et al.  Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. , 2003, Cancer research.

[21]  H. Friess,et al.  Adjuvant therapy in pancreatic cancer: historical and current perspectives. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  E. Solary,et al.  Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. , 2003, Pathology, research and practice.

[23]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[24]  R. Schmid,et al.  Genetic alterations in pancreatic carcinoma , 2003, Molecular Cancer.

[25]  H. Kalthoff,et al.  Apoptosis: Targets in Pancreatic Cancer , 2003, Molecular Cancer.

[26]  Boris Zhivotovsky,et al.  Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. , 2002, Experimental cell research.

[27]  Masahiko Miura,et al.  Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy. , 2002, Cancer research.

[28]  N. Giese,et al.  Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice , 2002, Cancer Gene Therapy.

[29]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[30]  J C Reed,et al.  The Survivin saga goes in vivo. , 2001, The Journal of clinical investigation.

[31]  J. Inazawa,et al.  Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. , 2001, Cancer research.

[32]  U. Boggi,et al.  Bcl‐2 expression in pancreas development and pancreatic cancer progression , 2001, The Journal of pathology.

[33]  A. Masamune,et al.  Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors , 2001, Cancer.

[34]  G. Giaccone,et al.  Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  R H Hruban,et al.  Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions , 2001, The American journal of surgical pathology.

[36]  H. Friess,et al.  Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. , 2001, Cancer letters.

[37]  S. Frisch,et al.  Anoikis mechanisms. , 2001, Current opinion in cell biology.

[38]  H. Friess,et al.  Enhanced expression of Silencer of death domains (SODD/BAG-4) in pancreatic cancer. , 2000, Biochemical and biophysical research communications.

[39]  Yili Yang,et al.  Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. , 2000, Science.

[40]  Stanley R. Hamilton,et al.  Pathology and genetics of tumours of the digestive system , 2000 .

[41]  P. Marynen,et al.  The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. , 1999, Blood.

[42]  H. Friess,et al.  Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. , 1998, Annals of surgery.

[43]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[44]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[45]  M. Korc,et al.  bax , but not bcl-2 , influences the prognosis of human pancreatic cancer , 1998 .

[46]  M. Malim,et al.  Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  K. Tamai,et al.  Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes , 1996, Nature.

[48]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[49]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[50]  A. Stout,et al.  Atlas of Tumor Pathology , 1954, American journal of clinical pathology.

[51]  Harlan I. Firminger,et al.  Atlas of tumor pathology , 1954 .

[52]  K. T. Steigelman.  Tumors of the pancreas. , 1951, The Journal of the American Osteopathic Association.